XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Taxes  
Income Taxes

Note 12. Income Taxes

We are subject to U.S. federal, state and foreign corporate income taxes. The (benefit) provision for income taxes is based on income (loss) before (benefit) provision for income taxes as follows (in thousands):

Year Ended December 31,

    

2021

    

2020

    

2019

 

U.S.

$

991,873

$

(16,609)

$

712,486

Non-U.S.

 

(421,429)

 

(215,609)

 

(225,695)

Income (loss) before (benefit) provision for income taxes

$

570,444

$

(232,218)

$

486,791

On a periodic basis, we reassess the valuation allowance on our deferred income tax assets. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

In the fourth quarter of 2021, we assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December 31, 2021, consistent growth in product revenues, and expectations regarding future profitability. We also assessed negative evidence, including the potential impact of competition, clinical failures and patent expirations on our projections. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that the majority of our U.S. deferred tax assets would be realized in the future and released the associated valuation allowance as of December 31, 2021. This resulted in a benefit of $569.0 million. As of December 31, 2021, we maintained a valuation allowance of $408.2 million against a portion of our remaining U.S. deferred tax assets as well as select state and foreign deferred tax assets.  

Our (benefit) provision for income taxes consists of the following (in thousands):

Year Ended December 31,

    

2021

    

2020

    

2019

Current:

Federal

$

50,565

$

43,595

$

23,526

State

32,505

18,881

11,553

Foreign

 

4,397

 

1,353

 

5,183

87,467

63,829

40,262

Deferred:

Federal

(407,852)

State

(57,677)

(205)

Foreign

(75)

(350)

(172)

(465,604)

(350)

(377)

Total (benefit) provision for income taxes

$

(378,137)

$

63,479

$

39,885

A reconciliation of income taxes at the U.S. federal statutory rate to the (benefit) provision for income taxes is as follows (in thousands):

Year Ended December 31,

    

2021

    

2020

    

2019

 

Provision (benefit) at U.S. federal statutory rate

$

119,793

$

(48,766)

$

102,226

State and local income taxes

34,461

(21,637)

15,109

Foreign tax rate differential

55,171

30,839

57,351

Income tax credits

(55,139)

(38,221)

(60,072)

Change in valuation allowance

(523,279)

158,815

(70,264)

Foreign-derived intangible income

(28,259)

(22,830)

(9,153)

Stock based compensation

15,497

2,802

(414)

Other

 

3,618

 

2,477

 

5,102

(Benefit) provision for income taxes

$

(378,137)

$

63,479

$

39,885

The foreign tax rate differential in the table above reflects the impact of operations in jurisdictions with tax rates that differ from the U.S. federal statutory rate of 21%.

Significant components of our deferred tax assets and liabilities are as follows (in thousands):

December 31,

  

2021

  

2020

 

Deferred tax assets:

Net operating loss carry forwards

$

137,935

$

128,088

Federal and state research credits

 

206,184

 

305,099

Capitalized research and development

 

59,247

 

43,806

Deferred revenue and accruals

 

42,326

 

27,467

Non-cash compensation

83,002

75,867

Acquisition-related contingent consideration

 

31,450

 

32,658

Intangibles, net

305,228

289,848

Long term investments

34,733

25,968

Other

 

15,991

 

26,422

Total gross deferred tax assets

 

916,096

 

955,223

Less valuation allowance for deferred tax assets

 

(408,180)

 

(930,209)

Net deferred tax assets

$

507,916

$

25,014

Deferred tax liabilities:

Property and equipment

$

(33,259)

$

(19,880)

Other

(7,119)

(3,080)

Total gross deferred tax liabilities

 

(40,378)

 

(22,960)

Net deferred tax assets

$

467,538

$

2,054

The valuation allowance for deferred tax assets decreased by approximately $522.0 million during the year ended December 31, 2021, increased by approximately $159.7 million during the year ended December 31, 2020 and decreased by approximately $66.5 million during the year ended December 31, 2019.  The net valuation allowance decrease during 2021 was primarily due to the valuation allowance release on the majority of our U.S. deferred tax assets mentioned above.

As of December 31, 2021, we had net operating loss (“NOL”) carryforwards, research and development credit carryforwards and orphan drug tax credit carryforwards as follows (in thousands):

Amount

Expiring if not utilized

Net operating loss carryforwards

State

$

296,112

2022 through 2041; indefinite

Foreign

1,422,407

2022 through 2028

Research and development credit carryforwards

Federal

114,595

2037 through 2041

State

21,062

2021 through 2040; indefinite

Orphan drug tax credit carryforwards

121,389

2036 through 2041

The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized, we would recognize a tax benefit of $50.1 million. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):

Year Ended December 31,

2021

 

2020

Balance at beginning of year

$

31,597

$

24,251

Additions related to prior periods tax positions

28,488

 

3,953

Reductions related to prior periods tax positions

(311)

(216)

Additions related to current period tax positions

3,042

 

4,119

Settlements

(95)

(201)

Reductions due to lapse of applicable statute of limitations

(288)

(397)

Currency translation adjustment

(74)

88

Balance at end of year

$

62,359

$

31,597

Our policy is to recognize interest and penalties related to uncertain tax positions, if any, as a component of income tax expense. During the year ending December 31, 2021, we recorded interest and penalties as a component of income tax expense of $0.6 million and during the year ended December 31, 2020, we recorded a negligible reduction to interest and penalties as a component of income tax expense. We do not anticipate any significant changes to our unrecognized tax benefits during the next twelve months.

We file U.S. federal, state and local income tax returns and income tax returns in various foreign jurisdictions, with statutes of limitation generally ranging from three to five years during which such tax returns may be audited by the relevant tax authorities. Those statutes could be extended due to NOL or tax credit carryforwards generated during these periods that are subsequently utilized in open tax periods.  In general, tax authorities have the ability to adjust the NOL carryforward or tax credits for three years after utilization of that year’s tax attribute carryforward.